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(r)HDL in theranostics: how do we apply HDL’s
biology for precision medicine in atherosclerosis
management?†
Kepa B. Uribe, a Asier Benito-Vicente, b Cesar Martin, b
Francisco Blanco-Vacac,d,e,f and Noemi Rotllan *d,f
High-density lipoproteins (HDL) are key players in cholesterol metabolism homeostasis since they are
responsible for transporting excess cholesterol from peripheral tissues to the liver. Imbalance in this
process, due to either excessive accumulation or impaired clearance, results in net cholesterol accumu-
lation and increases the risk of cardiovascular disease (CVD). Therefore, significant effort has been
focused on the development of therapeutic tools capable of either directly or indirectly enhancing HDL-
guided reverse cholesterol transport (RCT). More recently, in light of the emergence of precision nano-
medicine, there has been renewed research interest in attempting to take advantage of the development
of advanced recombinant HDL (rHDL) for both therapeutic and diagnostic purposes. In this review, we
provide an update on the different approaches that have been developed using rHDL, focusing on the
rHDL production methodology and rHDL applications in theranostics. We also compile a series of
examples highlighting potential future perspectives in the field.
1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality
worldwide, resulting in an estimated global mortality of
17.9 million people each year1 and remains a leading cause
despite pharmacological interventions for numerous risk
factors.2 The main risk factors for CVD are smoking, age, sex,
diabetes, obesity, hypertension and dyslipidaemias.3,4 In the
group of dyslipidaemias, dysregulation of cholesterol homeo-
stasis is one of the primary risk factors associated with the
development of atherosclerosis, the underlying cause of most
CVD. The main particles responsible for cholesterol transport
throughout the body are lipoproteins, macromolecular com-
plexes primarily composed of lipids and apolipoproteins. These
lipoproteins are classified by density, ranging from very low
density lipoproteins (VLDL) to high density lipoproteins (HDL).5
Interestingly, of the different types of lipoproteins capable of
cholesterol transport, only HDLs are able to remove excessive
cholesterol from peripheral tissues to the liver, a process known
as reverse cholesterol transport (RCT).6 Moreover, HDLs also
have additional beneficial characteristics that made these lipo-
proteins attractive candidates for managing or preventing ather-
osclerosis, such as their small size and ability to interact with
other receptors, their ability to encapsulate hydrophobic/hydro-
philic molecules, and other antiatherogenic functions. However,
the use of natural HDLs has some limitations and in order to
overcome them there has been significant research focused on
the development of reassembled HDL (rHDL), a field that has
grown due to the rise of precision nanomedicine. The potential
advantages of these rHDL are wide-ranging, including potential
use as natural drug-delivery carriers or contrast agents for
medical imaging. This review aims to overview a detailed proto-
col of the different purification, manipulation and modification
methods for developing (r)HDLs. In addition, this review also
describes the application of (r)HDL in therapeutics and has
compiled the most relevant pre-clinical studies and clinical
trials that are using (r)HDLs.
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2. HDL in health and disease
2.1 Natural HDL composition and metabolism
In 1960, HDL was first described after human plasma isolation
by ultracentrifugation. HDLs are the densest (1.063 < d <
1.21 g mL−1) and smallest (5 nm to 17 nm) plasma lipopro-
teins. HDL is a protein-rich particle with a hydrophobic core,
consisting of cholesteryl esters, triglycerides and unesterified
cholesterol, surrounded by a monolayer of phospholipids,
unesterified cholesterol and apolipoproteins. HDLs are hetero-
geneous in shape, size, density, composition and surface
charge and can be classified by density (ultracentrifugation),
size (gradient gel electrophoresis), surface charge (agarose gel
electrophoresis) or apolipoprotein composition (immunoaffin-
ity chromatography) (see Table 1).
HDL particles contain various apolipoproteins, of which
ApoA-I and ApoA-II are quantitatively the most abundant.7 In
addition to different apolipoproteins, a variety of enzymes and
lipid transport proteins are associated with HDL, composing
the protein component of this lipoprotein. These proteins,
such as lecithin : cholesterol acyltransferase (LCAT), cholesteryl
ester transfer protein (CETP) and phospholipid transfer
protein (PLTP), are crucial for HDL metabolism.
The use of proteomic and lipidomic technologies have
enabled the identification of over 85 proteins and more than
200 additional lipids which may reside within HDL particles,
as well as genetic material in the form of microRNAs that are
associated with HDL.8–10
Briefly, biogenesis of HDL occurs in the liver and intestine,
which are able to synthesize and secrete ApoA-I. The first step
in the formation of HDL is the interaction of a lipid poor
ApoA-I with the ATP binding cassette A1 transporter (ABCA1).
ABCA1 is a cholesterol-phospholipid transporter expressed by
enterocytes, hepatocytes and other cell types such as macro-
phages, that allows the nascent HDL to acquire lipids and
form preβ-HDL particles. ATP binding cassette G1 transporter
(ABCG1) is another protein that plays an important role in reg-
ulating cholesterol efflux, although its mechanism of action is
still controversial. Next, HDL acquires additional lipids and
apolipoproteins derived from the hydrolysis of triglyceride-rich
lipoproteins. LCAT acts on cholesterol in nascent HDL par-
ticles to generate cholesterol esters, which form the core of the
mature HDL particle.
Considering HDL catabolism, there are three main meta-
bolic pathways of cholesterol ester clearance in HDL: (1)
through direct uptake by the liver or steroidogenic tissues via
the HDL scavenger receptor BI (SR-BI); (2) through specific
and non-specific transfer of unesterified cholesterol to LDL;11
or (3) through transfer to apoB-containing lipoproteins by
CETP. CETP activity increases the triglyceride component of
HDL, which is susceptible to lipolysis by hepatic lipase (HL)
and endothelial lipase (EL). Upon modification by these two
enzymes, a smaller HDL particle is formed, which is suscep-
tible to faster catabolism. Consequently, HDL consist of a
group of particles with marked structural, compositional, phy-
siochemical and functional heterogeneity and with significant
differences in their biological activities.
Table 1 Classification of HDL subpopulations using different
methodologies
UC HDL2 (1.063 < density < 1.125 g ml
−1)
HDL3 (1.126 < density < 1.210 g ml
−1)
GGE HDL2b (mean diameter, 10.6 nm)
HDL2a (mean diameter, 9.2 nm)
HDL3a (mean diameter, 8.4 nm)
HDL3b (mean diameter, 8 nm)
HDL3c (mean diameter, 7.6 nm)
AGE α-HDL (lipid-containing spherical particles)
preβ-HDL (lipid-free or lipid-poor ApoA-I)
IAC LpA-I (with ApoA-I but without ApoA-II)
LpA-I/A-II (with both ApoA-I and ApoA-II)
UC, ultracentrifugation; GGE, gradient gel electrophoresis; AGE,
agarose gel electrophoresis; IAC, immunoaffinity chromatography;
LpA-I/A-II, lipoprotein A-I/A-II.
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2.2 The role of HDL in CVD protection/development
The main function of HDL in lipid metabolism is to allow
RCT, which consists of removing excess cholesterol from peri-
pheral tissues and delivering it to the liver, where cholesterol
is redistributed to other tissues or removed from the body in
the stool. In addition to this beneficial function, HDL has
other anti-atherosclerotic effects such as anti-inflammatory,
anti-oxidative, and anti-apoptotic functions and also improves
endothelial function.6 Historically, epidemiological studies
have shown an inverse association between serum HDL chole-
sterol (HDL-C) and the risk of cardiovascular events, support-
ing the theory that HDL is “the good cholesterol”.12,13 Because
of this, increasing plasma levels of HDL-C has long been con-
sidered a promising complementary therapy to the classical
statin-based LDL-C lowering strategy. However, studies con-
ducted in the past decade trying to prove a causal relationship
between high HDL-C values and lower CVD risk did not obtain
the expected results. On one hand, it has been shown that
there is no correlation between epidemiological and genetic
studies. There are several monogenetic studies conducted in
human individuals carrying genetic variants that naturally con-
dition them to low or high HDL-C levels that have unexpect-
edly demonstrated that high HDL-C levels are associated with
increased risk of coronary heart disease (CAD) and, by con-
trast, no harmful effects were observed when the concen-
trations were lower.14,15 In addition, a mendelian randomiz-
ation study found that although carriers of a loss-of-function
variant in the endothelial lipase gene presented with higher
HDL-C levels, with similar levels of other lipids and non-lipid
risk factors compared with non-carriers, they were not more
protected to myocardial infarction than would be expected
from observational epidemiology.16 Moreover, a GWAS-type
approach that reached hundreds of thousands of people and
studied 157 genetic loci associated with lipids levels could not
find any association between HDL-C and CAD risk when
focused on loci uniquely related to HDL-C levels.17 On the
other hand, studies that focused on evaluating the suitability
of the chemical intervention to raise HDL-C with therapeutic
purposes found this strategy not beneficial. Neither pharmaco-
logical CETP inhibition18–20,21 nor niacin administration22,23
resulted in meaningful therapeutic efficacy in the most recent
clinical trials.
In part, this set of unfavourable results could be explained
by the results of a recent study that has shown the existence of
a U-shaped association between HDL cholesterol concen-
tration and all-cause mortality.24 Together, the HDL-C levels
hypothesis has evolved to the HDL function hypothesis,
arising from evidence that suggests HDL “quality” may be
more clinically relevant than “quantity”.25 Thus, the specific
composition of HDL particles is crucial to the anti-atherogenic
functions mentioned before. As an example, high levels of
HDL-C in which HDL is dysfunctional may not only have no
clinical benefits but may even increase the risk of CVD. That is
why the focus in therapeutics has shifted to increasing the
anti-atherogenic function of HDL instead of simply increasing
HDL-C levels.26 Recently, it has been considered that a key
measure of HDL functionality is HDL cholesterol efflux
capacity (CEC) from macrophages. Specifically, a cross-sec-
tional study found that the CEC from macrophages is inversely
associated with both carotid intima-media thickness and the
likelihood of angiographic CAD, independent of HDL-C
levels.27 Some studies have found that increased efflux is
associated with reduced risk for CVD,28–30 while other studies
did not find this association.31 The discrepancies in these
studies may be due to the use of different techniques to quan-
tify CEC.
3. (r)HDL methodology: purification
or preparation, manipulation and
modification
Since the first papers describing alpha-lipoproteins purifi-
cation were published in early 1950s using Cohn’s method32
and subsequent attempts to their characterization,33 much
progress has been made in (r)HDL related laboratory tech-
niques and methodologies. Now, there are multiple well-estab-
lished protocols for plasma HDL purification, plasma or
recombinant ApoA-I purification and rHDL preparation.
Similarly, a set of biophysical approaches have been defined as
“standards” in order to make rHDL preparations. In the next
few sections, some schemes have been included to graphically
summarize the different purification/reconstitution methods.
In addition, we encourage the reader to look at the “3-step (r)
HDL purification/methods” that were included in the ESI† of
this article, where these methods have been explained in more
detail.
3.1. HDL and ApoA-I purification
Plasma HDL purification. Plasma is a blood biofluid com-
ponent primarily consisting of water along with proteins,
lipids and other metabolites. It is the main means of lipopro-
teins transport in their route throughout the body, and there-
fore represents the major source of HDL and other lipopro-
teins in purification. Lipoproteins can be obtained by sequen-
tial density ultracentrifugation (SD-UC) (Fig. 1) or fast protein
liquid chromatography (FPLC). Although the latter separation
method more accurately separates different lipoproteins speci-
mens, is not suitable for purification of large amounts of
HDL.34,35
ApoA-I purification from plasma. Some authors have used
human-derived ApoA-I directly purified from plasma for their
rHDL preparations. This is the case of CSL Behring labora-
tories, which developed HDL-mimetic nanoparticles (SRC-
rHDL/CSL-111 and CSL-112).36,37 This procedure is based on
the different properties of stability at varying pH, ethanol con-
centration, ionic strength, protein concentration and tempera-
ture of plasma components (Fig. 2).
r-ApoA-I purification. The second primary ApoA-I source is
the production and purification of a human recombinant
Biomaterials Science Review

































































































version from bacterial, yeast, mammalian or cell-free opti-
mized systems.38–41 Although concerns could arise from the
use of bacterial origin products and their potential immuno-
reactivity, their use has been proven to be safe. Indeed, compa-
nies such as The Medicines Company (MDCO-216)42 and
Cerenis Therapeutics (CER-001)43 have chosen this solution to
prepare their rHDL formulations. An excellent solution to
obtain enough concentration of a good quality human recom-
binant ApoA-I and in a quick fashion was developed in ref. 44.
They engineered a human wild type, full-length and mature
form of ApoA-I linked to a N-terminal histidine tag to allow
nearly one-step protein purification from E. coli cultures
(Fig. 3). Furthermore, the incorporation of cysteine substi-
tutions (i.e. L240C) keeps the functionality of the protein intact
and allows its labelling or modification.
3.2. rHDL preparation and biophysical characterization
Recombinant HDL nanoparticles are prepared using many
different procedures. As lipoprotein-mimetic nanostructures,
they consist of two main elements: proteins (or peptides) and
lipids. Studies on rHDL formation thermodynamics demon-
strated that although rHDL formation is favoured by an enthal-
pic component (mainly by α-helices folding after protein-lipid
complexation), rHDL cannot be formed spontaneously since
the activation barrier is markedly high.45 Various strategies to
overcome this energetic barrier have led to the development of
different methodologies for rHDL synthesis.
Sonication: Sonication was the first documented method
used for rHDL formation,46 but current use of this method-
ology has made some adaptations to the original protocol.47
The rationale of this method is based on the application of
ultrasound radiation to a lipid dispersion, which promotes the
formation of small unilamellar vesicles (SUV), reducing the
activation energy and facilitating ApoA-I incorporation and
nanoparticle production (Fig. 4).
Sodium cholate dialysis: This method was developed by Matz
and Jonas in the 1980s and has been one of the more com-
monly used methods.48 Conceptually, this technique seeks to
generate membrane disruptions by adding a non-denaturing
detergent (sodium cholate) to facilitate ApoA-I folding and its
insertion into the lipid bilayer, where is leads to generation of
rHDL particles (Fig. 5). It is a very effective and versatile meth-
odology for rHDL synthesis since the modification of the
initial lipid composition (usually phospholipids, sterols and
their derivatives) and/or the ApoA-I : lipid mole ratio enables
the formation of nanoparticles with different sizes and shapes.
This method has been chosen for SRC-rHDL/CSL-111 and
CSL112 preparations.36,37
Thermal cycling: Recently, a new methodology has been
described for rHDL formation using only ApoA-I peptides and
lipids as initial components.49 However, this methodology
could also potentially be applied using the whole ApoA-I
(Fig. 6). This method reduces the activation barrier by cycling
the temperature between lipid phase transition temperature
(Tm) and room temperature, facilitating the appearance of dis-
continuities in the membrane where ApoA-I can be incorpor-
ated. This technique generates a uniform nanodisc population
and is the most efficient method in terms of low waste
generation.
Microfluidics: In 2013, microfluidics was introduced to the
rHDL field in order to produce nanoparticles (denominated as
μHDL) in a more controlled fashion with less heterogeneity
(Fig. 7).50 This approach starts by directly mixing the lipids,
dissolved in an organic solution, with ApoA-I in buffer in a
very controlled condition provided by the architecture of a
microfluidic device. Once both fluids are injected into the
microfluidic device, the transition of lipids from organic to
aqueous solution leads to the formation of lipid aggregates in
a microvortice that facilitates the spontaneous incorporation
of ApoA-I into nanoparticles. Microfluidics has also been
applied with ApoA-I mimetic peptides in a recently developed
microfluidic platform51 and to the study of membrane proteins
incorporated into nanodiscs.52
High-pressure homogenization (HPH): Another technique that
has been used for rHDL preparations is the HPH procedure
(Fig. 8). This is the case of the MDCO-216 formulation.53 This
type of methodology is commonly used in industry to prepare
nanosuspensions, as it is easily scalable for commercial pur-
poses. HPH is a high-energy consuming procedure where the
final components of the preparation are broken down to nano-
scale particle size by the application of cavitation, shear and
collision forces.54 No specific information is available in the
literature regarding how MDCO-216 is produced by HPH.
Recently, more research laboratories have started adapting
their production methods to the HPH methodology in order to
scale up production.55
The biophysical characterization of rHDLs has to be designed
to analyse predominantly (1) the size (small, medium, large) and
morphology (disc vs. sphere) of the particles, (2) the protein/
lipid final composition (protein : lipid final mole or weight ratio;
final lipid composition and proportions; number of ApoA-I
molecules per particle), (3) the scaffold protein structure (%
alpha-helix), (4) the heterogeneity of the sample (polydispersity
index) and (5) the stability of the formulation (aggregation
index). Although not needed in routine work, the characteriz-
ation of rHDL requires a combination of different biophysical
techniques in order to have a complete and exhaustive vision of
rHDLs. In the case of modified or multifunctional nanoparticles,
complementary functional analyses must be undertaken. Even
though an in-depth comparative analysis of the different bio-
physical characterization techniques is not the subject of this
review, we will provide some illustrative bibliography of each
technique that may serve the reader (see Table 2).
3.3. Tailoring of (r)HDL
The major determinants of the rHDL physicochemical charac-
teristics and hence rHDL functionality are their constituents.
In this sense, many different rHDL preparations have been
described in which the composition of ApoA-I/peptides, lipids
and other modifications or cargo molecules are unique in
their configuration, yielding a final particular (r)HDL prepa-
ration with its own unique composition and characteristics.
Review Biomaterials Science

































































































Proteins. ApoA-I is the main apolipoprotein used as a mem-
brane scaffold protein for rHDL preparations. However, other
apolipoproteins such as ApoA-II, ApoA-IV, ApoE, ApoJ, serum
amyloid A (SAA) or synuclein variants have been described as
potential scaffolds for nanoparticle synthesis.78–83 Wild-type
apolipoprotein A-I (UniProtKB #P02647) is a 243 amino acid
long and 28 kDa weight amphipathic polypeptide. It is natu-
rally synthesized as pre-pro-ApoA-I, and after being intracellu-
larly processed, adopts the pro-form (pro-ApoA-I), which is
secreted for further processing in order to acquire its mature
form (ApoA-I). ApoA-I is secreted as lipid-free, or poor-lipidated
apolipoprotein, and is further lipidated, generating nascent
discoidal HDLs.84,85 A consensus ApoA-I monomeric and lipid
free model has been recently described. In this model, ApoA-I
is presented as a helical bundle composed by six helix (126
α-helical residues, 52%) organized around the N-ter and two
random coil regions, the largest located in the C-ter, that are
further folded after being lipidated.86 rHDL are generated
using different types of ApoA-I but the predominant types are
the human plasma-derived or recombinant mature ApoA-I,37,43
the recombinant pro-ApoA-I form (Pro-ApoA-I-liposome prepa-
ration from UCB SA laboratories),87,88 and natural ApoA-I vari-
ations such as ApoA-I Milano.42 It has also been synthetized in
a trimeric mature ApoA-I form.89
ApoA-I mimetic peptides. Alternatively, and in order to
reduce production costs, the amphipathic alpha-helices of
ApoA-I have been used as template to design a set of mimetic
peptides with similar properties to those of the whole apolipo-
protein, but also with unique features. These peptides do not
have sequence homology with ApoA-I but all resemble class A
amphipathic helices and have lipid binding capacities similar
to ApoA-I. They are able to stimulate ABCA1-mediated chole-
sterol efflux and have anti-inflammatory and antioxidant pro-
perties. To present, there are at least six families of mimetic
peptides: the 18A peptide and its derivatives (2F, 4F, 6F,
etc.);90,91 the bihelical peptide 37pA and its derivative 5A;92,93
the ETC-642 preparation, composed of the 22A peptide
ESP-242118 plus lipids;94 the A10 peptide and its derivatives
(S1A10 and S2A10);95 the Fukuoka University ApoA-I Mimetic
Peptide (FAMP) family of peptides;96 and mono- or bi-helical
ELK peptides.97
Lipids. Lipidomic studies have shown that the most abun-
dant lipids in HDL, measured as mol% of total, in healthy nor-
molipidemic patients are:9 phospholipids (phosphatidyl-
choline 32–35%; lysophosphatidylcholine 1.4–8.1%), sphingo-
lipids (sphingomyelin 5.6–6.6%) and neutral lipids (cholesteryl
esters 35–37%; free cholesterol 8.7–13.5%; triacylglycerides
2.8–3.2%). Since one of the main goals in rHDL generation
has been getting nanoparticles that resemble natural HDL, the
commonly used lipid compositions are phosphatidylcholine
lipid extracts [Pro-ApoA-I-liposomes: pro-ApoA-I + soybean
phosphatidylcholine (SPC); CSL-111/CSL-112: ApoA-I + SPC],
pure phospholipids or sphingolipids of different acyl chain
length and saturation (MDCO-216: ApoA-I Milano + 16:0/18:2
phosphatidylcholine), or combinations of lipids (CER-001:
ApoA-I + sphingomyelin + 16:0 phosphatidylglycerol; ETC-642:
ESP24218 peptide + 16:0 phosphatidylcholine +
sphingomyelin).36,37,43,48,49,59,88,94,98–100 For diagnostic pur-
poses, researchers have introduced some modified lipids in
their rHDL preparations. This is the case in the use of para-
magnetic lipids for magnetic resonance imaging (MRI) or
phospholipid chelators for positron emission tomography/
computed tomography (PET/CT).55,101 Finally, the lipid compo-
sition and the protein-to-lipid ratio will influence, among
others, size, shape and surface charge which can in turn influ-
ence rHDL biological functions.102,103
rHDL modifications. Due to current increasing interest in
HDL-mimetic nanoparticles, the development of new prep-
arations with enhanced functionalities has led to the expan-
sion of rHDL modifications. These modifications have been
adopted principally to tune HDL physicochemical properties
by (1) enhancing nanoparticle stability in biological fluids (via
rHDL PEGylation or lipid cross-linking),104,105 (2) improving
HDL targeting (dextran sulphate or hyaluronan modified
Table 2 Biophysical characterization of (r)HDL
Characteristic to
study Technique Ref.
Size • AUC 56 and 57
• SEC 58 and 59




• AFM 52, 65 and
66
• TEM/cryo-TEM 67 and 68
• SAXS/SANS 69 and 70
• NMR 71 and 72
Morphology • TEM/cryo-TEM 67 and 68
• AUC 57
• AFM 52, 65 and
66
• NMR 71 and 72









Protein structure • CD 75
• SANS 70
• NMR 71 and 72
• ATR-FTIR 59 and 76
Polydispersity • DLS 57
• AUC 57
Stability • ζ-Potential 77
• SEC 58 and 59
• DLS 57
AUC, analytical ultracentrifugation; SEC, size-exclusion
chromatography; PAGE, polyacrylamide gel electrophoresis; AGE,
agarose gel electrophoresis; DLS, dynamic light scattering; NTA,
nanoparticle tracking analysis; AFM, atomic force microscopy; TEM,
transmission electron microscopy; SAXS, small angle X-ray scattering;
SANS, small angle neutron scattering; NMR, nuclear magnetic
resonance; HPLC, high-performance liquid chromatography; MS, mass
spectroscopy; CD, circular dichroism; ATR-FTIR, attenuated total
reflection Fourier transformed infrared spectroscopy.
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rHDL) and/or controlling the release of cargo [poly(lactic-co-
glycolic acid) modified rHDL],103,106–109 and (3) allowing HDL
tracking or its use in medical imaging applications (fluores-
cently labelled ApoA-I, lipids or hyaluronan; contrast agents
for MRI, PET or CT).44,55,100,103,107,108
Cargo molecules. As mentioned above, rHDL are nanosized
particles (8–20 nm) with high tolerability in humans (up to
6.8 g ApoA-I per infusion), long half-life in blood (>24 h) and
intrinsic targeting properties.37,74,103 All these advantages have
led to rHDLs being considered as excellent nanocarriers for a
wide range of cargo molecules. rHDLs can accommodate both
hydrophilic compounds adsorbed or attached to the outer shell
or hydrophobic compounds entrapped in the core. rHDL cargo
can be designed to fulfil diagnostic or therapeutic functions
and has been used in studies in multiple fields, ranging from
cancer to neurodegenerative research.110–112 Within the CVD
field, there are many cargo molecules which have been studied
with therapeutic and diagnostic purposes. Among the mole-
cules with therapeutic properties are statins,113,114 LXR
agonists,103,115 bioactive lipids,116 immunomodulators,117
siRNA and miRNA molecules,118–120 as well as preparations
where more than one active component is combined.121,122 For
imaging applications, rHDL has been loaded with fluorescent
dyes or quantum dots for optical imaging,44,50,55,103,108,123,124
contrast agents as iron oxide or gadolinium for MRI,50,113,123,125
radionuclides as zirconium-89 (89Zr) for PET,55,103,117 or gold-
based rHDL for CT,50,123,126 among others.
4. (r)HDL in theranostics
Nanomedicine has emerged as a powerful tool that promoted
a qualitative leap in biomedicine, allowing us to see, under-
stand and modify with a precision level never seen before. It
allows us to focus on the nanoscale, but also allows us to
respond to daily challenges as well as to those that will come
from more comprehensive approaches, in which diagnosis and
treatment can be carried out in integrated steps. In this way,
theranostics is a term that embraces innovative solutions
attempting to combine agents that support “visualizing” and
diagnosing the problem together with the appropriate thera-
peutic in a single compound, preparation or device. One of the
prominent tools to study new theranostic approaches are
rHDLs, mainly in the field of CVDs, but also in other fields.
HDLs are biocompatible lipid–protein complexes that rep-
resent a promising scaffold for numerous nanobiotechnologi-
cal applications and have the potential to become a better
drug-delivery platform than liposomes, which are currently the
most widely used nanocarriers.127 As mentioned in prior sec-
tions, rHDLs are tailored and fully biocompatible nano-plat-
forms prepared in the laboratory that, together with their
intrinsic anti-atherosclerotic properties, are ideal candidates
for theranostic tool designing due to improved targeted deliv-
ery of both therapeutic compounds and/or imaging agents
such as contrasts.
Many laboratories have attempted to adapt their rHDL-
related translational research towards a more global theranos-
tic approach, although to date only a few attempts have
reached human clinical trials. We have recapitulated in the
main text some examples of the application of rHDLs as thera-
nostic tool/drug-delivery nanocarrier, but we designed the ESI
Table 2† with the intention of giving readers a great number of
sample cases where rHDL have been used as nanocarriers on
therapeutics. Thus, we encourage readers to visit the
additional information arranged in the ESI section.†
4.1. (r)HDL application in therapeutics
The idea of using lipoproteins for therapeutics was first pro-
posed in 1982.128 They have many characteristics that make
them promising candidates for therapeutics, such as their
small size, ability to interact with different receptors, selective
targeting capability, ability to encapsulate hydrophobic mole-
cules, hydrophilic exterior surface, lack of immunogenicity,
and extended residence time in circulation.
ApoA-I/HDL infusion. The first pre-clinical attempts to study
the therapeutic roles of (r)HDL in the field of CVD were carried
out in the late 1980s studying the effect of homologous HDL
infusions. Using adult New Zealand rabbits fed high-chole-
sterol diet as in vivo atherosclerosis model, the 50 mg per week
intravenous (IV) administration of purified HDL isolated from
normal rabbits led to a 60% reduction in the development of
atherosclerotic-like lipid-rich lesions and significantly
decreased lipid depositions in the artery wall compared to
control rabbits.129 Moreover, short-term (30 days) treatments
of 50 mg per week infusions were able not only to reduce
atherosclerosis progression but also to induce atherosclerotic
plaque regression by nearly 50%.130 Later in the mid-1990s, an
analogous approximation was carried out to test the anti-
atherogenic effect of non-lipidated ApoA-I infusions. In a
similar atherosclerotic model, the effect of rabbit purified
ApoA-I infusions was assessed using measurements of the pro-
gression and regression of atheroma lesions. This study found
that although 4 × 40 mg per week purified ApoA-I IV adminis-
tration pattern reduced progression of these lesions by 48%,
no regression was observed.131 In the same decade, the natural
variant ApoA-I Milano was also tested in vivo. It was known
that families carrying this mutation had very low levels of
HDL, due to an accelerated catabolism of the apolipoprotein,
and a drastically reduced CVD risk. Studies conducted in New
Zealand White rabbits on high-cholesterol diet and balloon
injury demonstrated that 10 day treatment, in a regiment con-
sisting of a 40 mg per dose every other day, reduced the
intimal thickness of injured arteries by 57–71% and reduced
the area of the intima covered by macrophages by more than
50%.132
It was not until the 2000s that studies like this were
extended to primates and humans. In a first approach, the
effect of human purified lipid-free ApoA-I IV bolus injection or
continuous infusion was studied in healthy patients with low
plasma HDL levels. This study tried to assess the effects, in
terms of safety and fate, of ApoA-I after a single-dose (a single
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injection or a continuous infusion over 5 h of 25 mg kg−1 of
ApoA-I) or a multi-dose treatment (6.25–50 mg kg−1 of ApoA-I
at different infusion rates over 5 h). The results showed that
the procedures were well tolerated with no clinical, biochemi-
cal or haematological changes and without evident immune
response. ApoA-I concentration in plasma increased in a dose-
dependent manner, with a mean half-life of >30 hours, and its
presence in plasma was concentrated in HDLs, particularly in
pre-β HDLs. Both attempts, ApoA-I bolus injection and con-
tinuous infusion, led to significant increases in phospholipid
levels in HDL and phospholipid and triglycerides levels in
non-HDL fractions but did not alter cholesterol levels in
HDL.133 Years later, a second round of trials was performed to
test the efficacy of selectively delipidated HDLs (HDL-sdl) to
promote reverse cholesterol transport and to promote athero-
sclerosis regression. By a process in which collected plasma
were treated with a series of organic solvents, researchers
managed to reduce HDL cholesterol in plasma by 77%, which
in turn resulted in enrichment of the pre-β1 HDL subspecies.
When primates were infused intravenously with a unique dose
of 22–23 mg kg−1 HDL-sdl plasma, these delipidated preβ-1
HDLs were rapidly converted into larger α-HDL with kinetic
behaviour depicting the RCT process. Subsequently, when the
same HDL-sdl dosage was infused weekly for a period of 12
weeks into monkeys that had developed atherosclerosis, treat-
ment was associated with a significant reduction of 6.9% in
the total atheroma volume analysed by IVUS, although the
change in the percentage of atheroma volume (PAV) did not
reach statistical significance.134 Finally, 28 patients with acute
coronary syndrome (ACS) and ≥1 non-obstructive native coron-
ary artery atheroma were enrolled in the LS-001 (Lipid Sciences
Selective Delipidation trial) study and treated for 7 weeks with
HDL-sdl plasma obtained from each patient plasma, collected
by apheresis and reinfused after delipidation. The results
showed that administration of the treatment was safe and well-
tolerated and, although not reaching statistical significance,
the change in mean atheroma volume represented a trend
towards reduction which was not observed in the control
group.135 In 2018, an innovative solution for treatment admin-
istration consisting of oral delivery of “APO milk” was pre-
sented. In this study, researchers successfully genetically
modified rice plants to express full-length ApoA-I Milano in
rice seeds and, after processing, obtained a protein extract con-
taining the therapeutic asset. When tested in an atherosclero-
sis rodent model as a 15-day treatment consisting of 5 days per
week by oral gavage of 0.83 mg kg−1 day−1 dose, there was a
significant reduction in atheroma plaque size of 35–50% as
well as favourable plaque remodeling.136
Lastly, an interesting pre-clinical study published also in
2018 shed some light into why pre-clinical studies on HDL-
raising approaches had not shown the benefits that are presup-
posed when they were transferred to humans. In this work,
there was a focus on the timing of when the ApoA-I/HDL is
administered and the effects of ApoA-I infusions in early- vs.
late-stage atherosclerotic lesions. ApoE−/− mice on a high-fat
diet for 8 weeks (early-stage) or 34 weeks (late-stage) were
treated with 40 mg kg−1 lipid-free ApoA-I infusions 2-to-3
times per week. The main result of the study was that while
ApoA-I induced plaque size reduction by 30% and improved
plaque stability as well HDL functionality in the early-stage
model, none of these beneficial effects were observed in the
late-stage model. Thus, the atheroprotective effects of ApoA-I/
HDL infusions likely depend, at least in part, on the plaque
development stage and/or the age of the subject of study.137
ApoA-I mimetic peptides. Another set of pre-clinical studies
has focused on the potential beneficial effects of ApoA-I short
mimetic peptide treatment. Due to the large number of papers
published with pre-clinical data, those most relevant to athero-
sclerosis are summarized in the ESI Table 1.† In addition to
short peptides, a longer peptide of 54 amino acids derived
from the C-terminal region of ApoA-I (peptide RG54) has been
shown to be beneficial for glucose control and for inhibiting
atherosclerosis.138 Moreover, some of the short mimetic pep-
tides have been tested in humans. The first candidate on this
bench-to-bedside journey was ETC-642 in 2002. Two different
single-dose studies in atherosclerotic patients and stable
cardiovascular patients showed that a single infusion of
ETC-642 was safe and well tolerated in a 0.1–20 mg kg−1
dosage. Then, a multiple-dose study was planned at 10–20 mg
kg−1 dosages in patients with stable cardiovascular disease,
but to date, there is no publicly available data on the
results.139 In 2008, the 4F peptide was assessed in humans for
the first time. In a phase I trial, patients with stable coronary
heart disease (CHD) or equivalent risk were treated with a
single oral dose of 30–500 mg of an unformulated D-4F
peptide preparation (also known as APP-018; Bruin Pharma
Inc.). The study found that although bioavailability was low,
the single dose was safe, well tolerated at all concentrations,
and could improve the HDL anti-inflammatory index.140 In a
subsequent study, the effect of an L-4F peptide preparation
(also known as APL180; Novartis Pharmaceuticals) was assayed
in patients with stable CHD or equivalent risk in a regimen of
7 days IV infusion or 28 days subcutaneous (SQ) injection.
Although the multi-dose IV or SQ administration was well-tol-
erated at all doses, it was not effective in improving bio-
markers of HDL anti-inflammatory function and a trend
toward an increase in inflammatory markers (hs-CRP and IL-6)
was noted (Clinicaltrials.gov # NCT00568594 and
NCT00907998).141 The last study conducted to date was in
2017 and in this occasion, the benefits of treatment with D-4F
as an oral multi-dose prescription were assessed. The study
subjects were high-risk CHD patients and were treated for 13
days with daily 100–500 mg dose. The D-4F oral treatment was
safe and well tolerated and resulted in reducing the HDL
inflammatory index by half. Interestingly, the peptide oral
dose was highly predictive of HDL inflammatory index
improvement while plasma D-4F level was unrelated, leading
to the conclusion that peptide penetration in the plasma may
be unnecessary.142
rHDL infusions. The study of rHDLs in a therapeutic context
has a long history, and a large number of both pre-clinical
studies in diverse disease models and clinical trials in human
Biomaterials Science Review

































































































Fig. 2 ApoA-I purification from plasma. A more detailed explanation can be found in the ESI section.† EtOH, ethanol; GdnHCL, guanidinium chlor-
ide. Purification protocol adapted from ref. 36 and references included in it.
Fig. 1 Plasma HDL purification by SD-UC. A more detailed explanation can be found in the ESI section.† QM, chylomicron; d, density. Purification
protocol adapted from ref. 34.
Fig. 3 r-ApoA-I purification from bacterial production system. A more detailed explanation can be found in the ESI section.† IMAC, immobilized
metal affinity chromatography. Purification protocol adapted from ref. 44.
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populations of various conditions have been conducted. Some
of the most relevant studies are summarized in the ESI Tables
2 (pre-clinical trials) and 3 (clinical trials).† Although rHDLs
have received high commercial interest, only a few compo-
sitions have been tested in clinical trials. We describe below
the formulations that have been tested in humans.
Pro-ApoA-I liposomes (UCB). This formulation consisting of
human pro-ApoA-I and SPC (1 : 45 mol ratio) demonstrated
that a single infusion of 40–50 mg kg−1 in patients with
Heterozygous Familial Hypercholesterolemia (HeFH) induced
body cholesterol mobilization and excretion with no safety
issues.88 Although promising, no other studies with this for-
mulation were found in the literature.
SRC-rHDL (ZLB Central Lab)/CSL-111 (CSL Limited)/CSL112
(CSL Behring). These are the only formulations prepared with
ApoA-I extracted from human plasma and the difference
between them lies in the ApoA-I : lipid mol ratio. All the formu-
lations contain ApoA-I and parenteral SPC grade; SRC-rHDL
and CSL-111 were prepared using 1 : 150 mol ratio while
CSL112 was prepared at 1 : 55 mol ratio. Both SRC-rHDL and
CSL-111 were the first to be tested and shown that a single
dose of 25–80 mg kg−1 promoted body cholesterol mobiliz-
ation and improved anti-inflammatory markers and atheroma
plaque.143,144 In 2007, the phase 2 ERASE trial was conducted
with 183 patients with ACS to test the effect of four weekly 40
or 80 mg kg−1 CSL-111 treatment on plaque burden. CSL-111
treatment failed at PAV reduction on IVUS, showing no signifi-
cant differences compared to placebo. Moreover, the study arm
receiving 80 mg kg−1 dose had to be discontinued early due to
safety concerns.145 Therefore, the formulation was modified in
order to improve its efficacy and safety profile. The new formu-
lation, CSL112, was satisfactorily tested in phase I/2a trials
with a favorable efficacy profile and no safety concerns in both
single and multiple dosages,37,146–148 but again failed in
efficacy when studied in a larger trial. AEGIS-1 was a phase 2b
trial completed in 2016 in which four weekly doses of 2 or 6 g
ApoA-I per dose were infused in 1258 patients with a recent
history of type I myocardial infarction. The results showed that
the coprimary safety endpoints, hepatotoxicity rate and renal
toxicity, did not show differences when compared to placebo.
Although the study was not primarily designed to analyze the
efficacy of CSL112, the time to first occurrence of a major
adverse cardiovascular event (MACE) was registered during a
12-month follow up in the intent-to-treat group, showing that
the risk of MACE was similar to placebo, indicating absence of
therapeutic effect.149 Currently, the AEGIS-II study
(NCT03473223) is being carried out to analyze the effect of
CSL112 in a large population of more than 17 000 people. This
study will evaluate the safety and the efficacy of CSL112 in sub-
jects with ACS diagnosis and myocardial infarction and is esti-
mated to be completed by the first half of 2022. Hopefully, the
rationale used in the design of the study will enable testing
the CVD benefits of an rHDL preparation with improved CEC
capacity.150
ETC-216 (Esperion Therapeutics-Pfizer)/MDCO-216 (The
Medicines Company-Novartis). First ETC-216 and later
MDCO-216, both were formulated using ApoA-I Milano and
1-palmitoyl-2-oleoyl-glycero-3-phosphocholine (POPC) at a
1 : 40 mol ratio. After an extensive pre-clinical validation,
ETC-216 was shown to be able to mobilize body cholesterol in
healthy volunteers and was well tolerated up to doses of
50–75 mg kg−1.151 In 2003, the results of the phase II “The
ApoA-I Milano Trial” study showed that ETC-216 promoted a
mean 2.7% coronary atherosclerosis regression in ACS patients
treated with 15 mg kg−1 or 45 mg kg−1 IV infusions.152 Despite
these promising results, clinical development of ETC-216 was
discontinued due to serious adverse effects in some patients.
After significant improvements in the manufacturing process,
the new formulation MDCO-216 was tested and proven to be
safe in terms of immunostimulatory effects.153 Therefore, the
phase I/II MILANO-PILOT study was designed to assess the
efficacy of 5 weekly 20 mg kg−1 MDCO-216 IV infusions in
statin-treated patients with ACS. The analysis of the results
showed that although MDCO-216 tended to reduce the PAV,
the reduction was not significantly different from placebo.154
Hence, it became clear that MDCO-216 treatment was not
effective in patients with established and intensive ACS treat-
ment as it was not able to reduce the residual risk in these
patients. A second phase II trial, MILANO-DRIVE, was
designed to be conducted in subjects with CAD and recent
ACS, but it was discontinued in 2016 due to lack of efficacy.
After that, The Medicine Company stopped investigating
MDCO-216 in 2016.
CER-001 (Cerenis Therapeutics). CER-001 represents the most
complex formulation. The scaffold protein is a recombinant
version of human ApoA-I produced in eukaryotic cultures and
the lipid mixture is composed of sphingomyelin and 1,2-dipal-
mitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DPPG). The final
mol ratio of ApoA-I : SM : DPPG is of 1 : 103 : 3. In 2013 the
phase II CHI SQUARE trial was completed in ACS patients to
test the efficacy of the treatment on total atheroma volume
reduction by the end of the study compared to baseline.
CER-001 was not effective and there were some safety issues
related to the treatment in some study subjects.43
Nevertheless, CER-001 was further tested in a new phase II
MODE trial in patients with phenotypic characteristics of
homozygous familial hypercholesterolemia (HoFH). Unlike
what was observed in the CHI-SQUARE trial, the results of the
MODE trial were favorable and found that 12 biweekly treat-
ments at 8 mg kg−1 dose resulted in a significant carotid mean
vessel wall area reduction.155 A post-hoc analysis of data
extracted from the CHI-SQUARE trial showed that the subjects
with the most extensive plaque-burden (baseline plaque ather-
oma volume ≥30%) receiving 3 mg kg−1 had the greatest
benefit since the treatment with CER-001 was statistically
effective compared to placebo in these conditions.156 Hence, a
phase II CARAT trial was attempted in ACS patients with these
characteristics. In this trial, patients on statin-therapy were
administered 10 weekly doses of 3 mg kg−1 CER-001 by IV infu-
sion and the efficacy on reduction of PAV from baseline was
analyzed after 78 days. Once again, the results were not favor-
able as CER-001 was unable to promote atherosclerosis
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Fig. 5 rHDL preparation/reconstitution by the sodium cholate dialysis method. A more detailed explanation can be found in the ESI section.† Tm,
lipid phase transition temperature; SEC, size-exclusion chromatography. Reconstitution protocol adapted from ref. 48.
Fig. 6 rHDL preparation/reconstitution by the thermal cycling method. A more detailed explanation can be found in the ESI section.† Tm, lipid
phase transition temperature; RT, room temperature; SEC, size-exclusion chromatography. Reconstitution protocol adapted from ref. 49.
Fig. 4 rHDL preparation/reconstitution by the sonication method. A more detailed explanation can be found in the ESI section.† Tm, lipids phase
transition temperature; SEC, size-exclusion chromatography. Reconstitution protocol partially adapted from ref. 47.
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regression.157 The last of the assays with CER-001 on humans
carried out in the phase II SAMBA trial was focused on deter-
mining CER-001 effects on RCT and the arterial vessel wall on
patients with Familial Hypoalphalipoproteinemia (FHA). The
study concluded that a 28 infusion treatment mobilized body
lipids, with a positive trend toward increased fecal sterol
excretion, but more importantly, it was effective in thinning
the carotid artery vessel wall and reducing arterial wall inflam-
mation.158 In 2018, a phase III TANGO trial was designed to be
carried out in a larger population of FHA patients but, due to
lack of efficacy, it was terminated prematurely.
Other preparations. Many other innovative formulations
developed in recent years have only been tested in vitro and in
animal models, with some of them showing high potential for
further evaluation in clinical trials. Most of the new rHDL
preparations sought to exploit their characteristics as specific
and targetable nanocarriers to “load” them with therapeuti-
cally active compounds (e.g. statins, immunomodulatory drugs
or siRNA/miRNA molecules) and enhance their intrinsic
efficacy, reducing in turn the side effects of the
payloads.113,117,122 On the other hand, other preparations
sought to increase the residence time of rHDL-cargo in the
system in order to increase the vector’s therapeutic effect (e.g.
rHDL PEGylation, LCAT inhibitors or cargo liberation control-
ling polymers) or improve/adapt its targeting capacity (e.g. hya-
luronic acid or anionic lipids), thus limiting cargo release in
unwanted cells/tissues.104,121,159,160
4.2. (r)HDL application in diagnostics
Similar to the applications of rHDLs in therapeutics, several
works have shown an increasing role of rHDL in diagnostics
too. Although the focus of this review is the application of
rHDL in atherosclerotic cardiovascular disease, increasing evi-
dence suggests that rHDLs could be successfully used as diag-
nostic tools in additional fields such as oncology. This feature
is due to their nanoscale size, their receptor-guided specificity
and their capacity to be loaded with contrast agents or tracers
of diverse natures. In the case of atherosclerosis, these advan-
tages enable specifically targeting the tracer to the atheroma
plaque, penetrating into it and marking the regions where
lesions are in an active state. At the pre-clinical level, rHDLs
have been tested for use with MRI, CT, PET and Near-infrared
(NIR) imaging for diagnostic applications.
The development of the rHDLs was initially dominated by
their potential role in therapeutics, which is why it was not
until the 21st century that rHDLs were evaluated in diagnostic
in vivo studies. Preliminary attempts studied the biodistribution
of 125I-HDLs in animal models and their binding to regions of
the aorta especially affected by lipid depositions by autoradiog-
raphy.161 Since 2004, however, rHDLs have begun to be systema-
tically used as in vivo imaging tools. That year and for the first
time, the combination of a gadolinium chelating modified
phospholipid (Gd3+-DTPA-DMPE) with rHDLs was shown to be
a useful contrast agent for MRI-based atheroma plaque detec-
tion, specifically in atherosclerosis model animals.162 Similar
positive results were obtained when Gd3+-DTPA-DMPE was
reconstituted in disk-shaped instead of spherical rHDLs or
when full ApoA-I was substituted by the 18A or 37pA mimetic
peptides.163–165 Subsequent studies showed a significant
improvement in MRI signal when substituting the ApoA-I for its
oxidized form, apparently due to an increased uptake by plaque
macrophages.166,167 Furthermore, it is feasible to track the
signal of ApoA-I or any of its mimetic peptides in vivo by co-
valently binding Gd3+ to ApoA-I by selective cysteine substi-
tution, zirconium-89 to lysine residues via deferoxamine B con-
jugation (89Zr-AI-HDL) or gallium-68 radiolabeling of FAMP pep-
tides (68Ga-DOTA-FAMP).168–170 The synthesis of a phospholipid
coordinated to 68Ga for its use with rHDL (68Ga-
PCTA-DSPE-HDL) has also been reported.171 In 2009, a new
rHDL nanoplatform concept was designed for imaging pur-
poses by combining Au, FeO or quantum dots (QD) nanocrystal
core with a phospholipid corona bearing fluorescent or para-
magnetic lipids. When tested, it was shown that this multi-
modal contrast agent was useful for in vivo T1- and T2-weighted
MRI, CT and fluorescence imaging.123 The in vivo application of
Au-rHDL was further validated in a multicolor CT study in com-
bination with other contrast agents.172 The last step carried out
in imaging mediated pre-clinical diagnostics is the multimodal
approach. Thus, in a study published in 2019, the authors
showed how combining 89Zr-rHDL and other functional radio-
tracers with PET, CT, MRI and NIRF imaging allows studying
the pharmacokinetics, biodistribution, and the anti-athero-
sclerotic effects of an rHDL-based nanoimmunotherapy.55
To date, only a single human imaging study related to ather-
osclerosis has been conducted, the Netherlands Trial Registry –
NTR5178, with the purpose of studying in vivo the delivery of
89Zr-labelled CER-001 to atheroma plaques of patients with
CAD. After a single infusion of 3 mg kg−1 of CER-001 together
with 89Zr-CER-001 (10 mg–18 MBq), patients were monitored by
serial PET/CT imaging and contrast-enhanced MRI for
48 hours. The study concluded that CER-001 targets the ather-
oma plaque and that is actively uptaken by cells, and can corre-
late with plaque contrast enhancement.173
5. Concluding remarks
CVD management continues to be one of the leading bio-
medical challenges of recent times, in part due to the rise of
ageing populations, as well as the growing trend of CVD-pro-
moting lifestyle factors. The pharmacologic objectives that
have been pursued for atherosclerosis prevention and
regression include reduction of the underlying systemic
inflammation and correction of the dysregulation generated by
increases in atherogenic lipid fractions. Cholesterol is one of
the central lipid molecules whose dysregulation is associated
with CVD development. Guided by knowledge acquired about
cholesterol metabolism, two basic strategies have been
implemented: reducing pro-atherogenic particles rich in chole-
sterol (“bad cholesterol”) or increasing those particles whose
purpose is to remove excess cholesterol (“good cholesterol”).
HDLs are included in this second group and for that reason
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have attracted the attention of many investigators as potential
therapeutic targets. HDLs are a dynamic and heterogenous
group of lipoproteins whose main function is to redistribute
excess cholesterol from peripheral tissues to the liver to be ulti-
mately excreted as stool, a process known as reverse cholesterol
transport.
Although the epidemiological studies identified a positive
correlation between increased HDL-C levels and a reduction in
CVD risk, subsequent genetic studies and large clinical trials
with HDL-C promoting drugs did not obtain positive expected
results that demonstrated a clear causal relationship.
Furthermore, it has been described that certain HDL popu-
lations could have pro-atherogenic properties. For these
reasons, the exogenous administration of purified HDLs or
reconstituted (r)HDLs has been proposed as an alternative
therapeutic solution that could accommodate current “quality”
parameters by designing or modifying rHDL on demand. As
has come up throughout this review, this is a key feature
rHDLs offer to researchers: the capability to improve on the
quality of HDLs through the enhancement of current anti-
atherosclerotic capabilities or by acquiring new properties
through incorporation of specific compounds. Inspired by
this, we may name such optimized rHDL particles as tailored
or “smart” rHDLs.
Of all the proposed rHDLs studied in vitro, only four rHDL
formulations (Pro-ApoA-I liposomes; SRC rHDL/CSL-111/
CSL112; ETC-216/MDCO-216; CER-001) have been studied in
humans. After thorough validation in pre-clinical studies, they
have been predominantly tested in patient cohorts with CVD
as a single or multi-weekly IV dose regimen. Unfortunately,
results have not been satisfactory for most of these candidates.
In fact, only one Phase 3 study (AEGIS-II) sponsored by CSL
Behring in a cohort of 17 400 patients with ACS is currently
taking place. The lack of statistically significant outcomes in
Fig. 7 rHDL preparation/reconstitution by microfluidics. A more detailed explanation can be found in the ESI section.† μHDL, recombinant HDL
made by microfluidic devices. Reconstitution protocol adapted from ref. 50.
Fig. 8 rHDL preparation/reconstitution by HPH method. A more detailed explanation can be found in the ESI section.† Reconstitution protocol par-
tially adapted from ref. 55.
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large clinical trials to date has led to doubts about the clinical
application of this therapeutic strategy. It is noteworthy
however that two of the successful earlier-stage studies were
focused on familial hypercholesterolemia, a disease in which
we know there is an impairment of reverse cholesterol trans-
port.11 Additionally, in animal models, HDL has shown to be
more protective in initial that advanced lesions. Given the
current knowledge that modified HDL can be converted into
pro-inflammatory particles with impaired reverse cholesterol
transport capacities, this could at least partially explain the
limited advances towards clinical application so far. In con-
trast, there is accumulating evidence that is positioning the
tailored manufactured, new generation of rHDLs as suitable
biocompatible nanocarriers for the development of future
theranostic approaches (Fig. 9 and ESI Tables 1 and 2†).
Although none of these advanced formulations have been
tested on humans yet, accumulating evidence from both
in vitro and in pre-clinical studies has demonstrated promise.
For atherosclerosis management, the designed tailored rHDL
undergo modifications/adaptations that enhance their athero-
protective function. In pre-clinical studies, newly assayed
ApoA-I variations (e.g. V156K variant or trimeric ApoA-I) or an
improved generation of mimetic peptides (e.g. the trimeric
A-10 or i-FAMP-D1 peptides) have better functional profiles
than their predecessors. Also, it has been recently demon-
strated in vitro that different lipid compositions of rHDL can
modulate cholesterol efflux activity stimulation,174 thus
demonstrating the importance of optimal lipid compositions
of rHDL in maximizing cholesterol efflux and achieving thera-
peutic objectives. In addition to optimizations of rHDL com-
ponents, rHDL has also been improved through chemical
modifications or addition of active compounds that enhance
rHDL’s biodistribution and bioavailability (e.g. rHDL
PEGylation or addition of gangliosides, hyaluronic acid or
LCAT activity modulators). On the other hand, what is more
interesting is the incorporation of active compounds into
rHDLs with therapeutic purposes, since rHDLs gather drug-
delivery nanocarrier properties. The combination of rHDL with
statins, immunomodulatory drugs or siRNA/miRNA molecules
has a profound synergistic effect, as it improves the efficacy
parameters compared to treatment with bare rHDL.
Specifically, when a bioactive compound is given in conjunc-
tion with rHDLs, the effects of the carried compound occurs
more locally, where it is needed, and unwanted side effects are
minimized. A clear example of this is noted when compared
the efficacy of the treatments of the ETC-642 formulation with
the LXR agonist T1317 inside or administered in parallel, as it
is published very recently.175 In both cases the concomitant
Fig. 9 Scheme/summary of the main results obtained in the different pre-clinical and clinical studies and some of the innovative modifications
applied to rHDLs. To have a broader view of the studies carried out as well as the particular formulations that have been studied, we encourage the
reader to see the different tables in the ESI section.†
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administration of rHDL + T1317 shows a positive synergistic
effect, although it is clearly superior in terms of atheroma
burden reduction the treatment of the loaded nanocarrier.
Complementing the advances in the therapeutic plane and
giving it the dimension of a theranostic tool, tailored rHDL
have also been developed to fulfil needs in imaging-based
studies. In this sense, rHDL have been specifically labelled
for PET, MRI, CT or NIRF imaging, leading to demonstration
of rHDL’s usefulness not only for diagnosis but also as a
tracer for functional studies. A great example of the potency of
tailored rHDL as a theranostic tool is the very recently pub-
lished work carried out by Binderup and colleagues55 and
which will be called to serve as an example for the next
developments.
For future, the development of a new generation of tailored
rHDL with improved characteristics and added functionalities
that, in general, constitute better “quality” HDL should serve
to attract the attention of researchers and investors and
relaunch interest in the development of new clinical trials in
humans to assess the capabilities of optimized rHDL as a ther-
anostic tool.
Abbreviations
ACS Acute coronary syndrome
Apo Apolipoprotein
ABCA1/G1 ATP-binding cassette A1 or G1 transporter
CAD Coronary artery disease
CEC Cholesterol efflux capacity
CHD Coronary heart disease
CVD Cardiovascular disease









DTPA Diethylenetriamine penta acetic acid
EL Endothelial lipase
FAMP Fukuoka apolipoprotein A-I mimetic peptide
FH Familial hypercholesterolemia
FHA Familial hypoalphalipoproteinemia

















LXR Liver X receptor
MACE Major adverse cardiovascular event
μHDL rHDL produced with microfluidics techniques
miRNA micro-RNA
MRI Magnetic resonance imaging
NIR Near-infrared
PAV Percentage of atheroma volume
PCTA Polycyclohexylenedimethylene terephthalate acid
PEG Polyethylene glycol
PET Positron emission tomography
PLTP Phospholipid transfer protein
POPC 1-Palmitoyl-2-oleoyl-glycero-3-phosphocholine
pro-ApoA-I Pro-form of apolipoprotein A-I
QD Quantum dot
r-ApoA-I Recombinant version of apolipoprotein A-I
RCT Reverse cholesterol transport
(r)HDL Combination of recombinant and natural HDL
SAA Serum amyloid A
SD-UC Sequential density ultracentrifugation
SEC Size-exclusion chromatography




SR-BI Scavenger receptor class B type I
SUV Small-unilamellar vesicle
Tm Phase transition temperature
VLDL Very low-density lipoprotein
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